Financial Review: BG Medicine (BGMD) versus Akers Biosciences (AKER)

BG Medicine (OTCMKTS:BGMD) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Insider & Institutional Ownership

7.7% of Akers Biosciences shares are held by institutional investors. 6.5% of BG Medicine shares are held by insiders. Comparatively, 8.9% of Akers Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for BG Medicine and Akers Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BG Medicine 0 0 0 0 N/A
Akers Biosciences 0 0 0 0 N/A

Profitability

This table compares BG Medicine and Akers Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BG Medicine N/A N/A N/A
Akers Biosciences -266.60% -97.10% -76.75%

Risk and Volatility

BG Medicine has a beta of 3.13, meaning that its share price is 213% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of -1.53, meaning that its share price is 253% less volatile than the S&P 500.

Earnings and Valuation

This table compares BG Medicine and Akers Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BG Medicine $1.57 million 0.14 -$5.30 million N/A N/A
Akers Biosciences $3.93 million 8.14 -$7.36 million N/A N/A

BG Medicine has higher earnings, but lower revenue than Akers Biosciences.

Summary

BG Medicine beats Akers Biosciences on 5 of the 9 factors compared between the two stocks.

About BG Medicine

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About Akers Biosciences

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth ?Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Receive News & Ratings for BG Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply